JP2002524529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002524529A5 JP2002524529A5 JP2000569831A JP2000569831A JP2002524529A5 JP 2002524529 A5 JP2002524529 A5 JP 2002524529A5 JP 2000569831 A JP2000569831 A JP 2000569831A JP 2000569831 A JP2000569831 A JP 2000569831A JP 2002524529 A5 JP2002524529 A5 JP 2002524529A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antagonist
- alpha4
- binding agent
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 33
- 239000005557 antagonist Substances 0.000 description 17
- 239000011230 binding agent Substances 0.000 description 13
- 108010041012 Integrin alpha4 Proteins 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 239000012634 fragment Substances 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 150000003384 small molecules Chemical group 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10018298P | 1998-09-14 | 1998-09-14 | |
| US60/100,182 | 1998-09-14 | ||
| PCT/US1999/021170 WO2000015247A2 (en) | 1998-09-14 | 1999-09-13 | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010132110A Division JP5378303B2 (ja) | 1998-09-14 | 2010-06-09 | インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002524529A JP2002524529A (ja) | 2002-08-06 |
| JP2002524529A5 true JP2002524529A5 (enExample) | 2006-09-07 |
Family
ID=22278506
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000569831A Pending JP2002524529A (ja) | 1998-09-14 | 1999-09-13 | インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法 |
| JP2010132110A Expired - Fee Related JP5378303B2 (ja) | 1998-09-14 | 2010-06-09 | インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法 |
| JP2013154324A Pending JP2013241441A (ja) | 1998-09-14 | 2013-07-25 | インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010132110A Expired - Fee Related JP5378303B2 (ja) | 1998-09-14 | 2010-06-09 | インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法 |
| JP2013154324A Pending JP2013241441A (ja) | 1998-09-14 | 2013-07-25 | インテグリンアンタゴニストを用いて多発性骨髄腫および骨髄腫誘導骨吸収を治療する方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7211252B2 (enExample) |
| EP (2) | EP2065050A1 (enExample) |
| JP (3) | JP2002524529A (enExample) |
| KR (1) | KR100628818B1 (enExample) |
| CN (1) | CN1236815C (enExample) |
| AT (1) | ATE418999T1 (enExample) |
| AU (1) | AU757873B2 (enExample) |
| BR (1) | BR9913705A (enExample) |
| CA (1) | CA2343579C (enExample) |
| CY (1) | CY1109413T1 (enExample) |
| CZ (1) | CZ302997B6 (enExample) |
| DE (1) | DE69940206D1 (enExample) |
| DK (1) | DK1113810T3 (enExample) |
| EA (1) | EA004270B1 (enExample) |
| EE (1) | EE05558B1 (enExample) |
| ES (1) | ES2319831T3 (enExample) |
| HU (1) | HU229038B1 (enExample) |
| IL (2) | IL141877A0 (enExample) |
| IS (1) | IS2631B (enExample) |
| NO (2) | NO327855B1 (enExample) |
| NZ (1) | NZ511062A (enExample) |
| PL (1) | PL203114B1 (enExample) |
| PT (1) | PT1113810E (enExample) |
| SI (1) | SI1113810T1 (enExample) |
| SK (1) | SK287601B6 (enExample) |
| TR (1) | TR200100734T2 (enExample) |
| WO (1) | WO2000015247A2 (enExample) |
| ZA (1) | ZA200102032B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| PT1214091E (pt) * | 1999-09-14 | 2006-09-29 | Imperial College | Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina |
| US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| AU2002356180A1 (en) * | 2001-08-06 | 2003-03-10 | The Regents Of The University Of California | Methods for inhibiting angiogenesis |
| EP2394652A3 (en) * | 2004-02-06 | 2012-10-24 | Elan Pharmaceuticals Inc. | Methods and compositions for treating tumors and metastatic disease |
| WO2007092471A2 (en) * | 2006-02-03 | 2007-08-16 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
| WO2007146188A2 (en) * | 2006-06-07 | 2007-12-21 | The Board Of Trustees Of The Leland Stanford Junior University | Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| SG189769A1 (en) | 2008-01-03 | 2013-05-31 | Scripps Research Inst | Antibody targeting through a modular recognition domain |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| KR101238061B1 (ko) * | 2009-03-31 | 2013-02-27 | 한화케미칼 주식회사 | Ｖｃａｍ－１에 특이적으로 결합하는 인간 단일클론항체 및 그를 포함하는 염증성 질환 또는 암의 치료용 조성물 |
| HUE050858T2 (hu) * | 2010-04-16 | 2021-01-28 | Biogen Ma Inc | VLA-4 ellenes antitestek |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| CA2840577A1 (en) * | 2011-06-30 | 2013-01-03 | Immuno-Biological Laboratories Co., Ltd. | Soluble integrin .alpha.4 mutant |
| EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| CN103215223B (zh) * | 2013-03-18 | 2014-10-29 | 中国人民解放军第四军医大学 | 人椎间盘髓核细胞和免疫细胞相互作用的体外模型构建方法 |
| CN103838980A (zh) * | 2014-03-27 | 2014-06-04 | 山东大学 | 对多发性骨髓瘤骨病治疗方法的疗效进行模拟评测的方法 |
| CN109498799A (zh) * | 2016-03-13 | 2019-03-22 | 曹帅 | 一种用于治疗骨髓增生、骨癌的药物组合物及其用途 |
| WO2017205560A1 (en) * | 2016-05-27 | 2017-11-30 | Albert Einstein College Of Medicine, Inc. | Methods for treating cancer by targeting vcam1 and maea |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| TW202504919A (zh) | 2023-05-30 | 2025-02-01 | 美商派拉岡醫療公司 | α4β7整合素抗體組合物及使用方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5272263A (en) | 1989-04-28 | 1993-12-21 | Biogen, Inc. | DNA sequences encoding vascular cell adhesion molecules (VCAMS) |
| US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
| US5217870A (en) | 1989-04-28 | 1993-06-08 | Biogen, Inc. | Monoclonal antibodies against CDX |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5260277A (en) | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
| WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
| US5871734A (en) | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| WO1993013798A1 (en) | 1992-01-13 | 1993-07-22 | Biogen, Inc. | Treatment for asthma |
| US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| ES2103468T3 (es) | 1992-02-12 | 1997-09-16 | Biogen Inc | Tratamiento de la inflamacion intestinal. |
| AU689454B2 (en) | 1992-11-13 | 1998-04-02 | Board Of Regents Of The University Of Washington, The | Peripheralization of hematopoietic stem cells |
| WO1994015958A2 (en) | 1993-01-08 | 1994-07-21 | Tanabe Seiyaku Co., Ltd. | Peptide inhibitors of cell adhesion |
| CA2153692C (en) | 1993-01-12 | 2011-11-08 | Roy R. Lobb | Recombinant anti-vla4 antibody molecules |
| ES2114183T5 (es) | 1993-02-09 | 2006-06-16 | Biogen Idec Ma, Inc. | Anticuerpo para el tratamiento de la diabetes dependiente de la insulina. |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| AU703152B2 (en) * | 1994-01-25 | 1999-03-18 | Biogen Ma Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US5510332A (en) * | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US5885786A (en) * | 1996-04-19 | 1999-03-23 | John Wayne Cancer Institute | Methods for screening of substances for inhibition of multidrug resistance |
| DE69735888T2 (de) | 1996-06-27 | 2006-11-02 | Chugai Seiyaku K.K. | Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoffsenfgasen verwendet werden kann |
| ATE256659T1 (de) * | 1998-05-28 | 2004-01-15 | Biogen Inc | Ein vla-4-inhibitor: omepupa-v |
| US9501219B2 (en) | 2012-01-25 | 2016-11-22 | Oracle International Corporation | 2D line data cursor |
| US9713013B2 (en) | 2013-03-15 | 2017-07-18 | Elwha Llc | Protocols for providing wireless communications connectivity maps |
| US9400266B2 (en) | 2013-03-14 | 2016-07-26 | Rosemount Analytical Inc. | Gas chromatograph with improved operation |
| US9104862B2 (en) | 2013-04-01 | 2015-08-11 | Uniquesoft, Llc | Secure computing device using new software versions |
-
1999
- 1999-09-13 KR KR1020017003274A patent/KR100628818B1/ko not_active Expired - Fee Related
- 1999-09-13 ES ES99949656T patent/ES2319831T3/es not_active Expired - Lifetime
- 1999-09-13 PL PL347128A patent/PL203114B1/pl unknown
- 1999-09-13 EP EP08016882A patent/EP2065050A1/en not_active Withdrawn
- 1999-09-13 WO PCT/US1999/021170 patent/WO2000015247A2/en not_active Ceased
- 1999-09-13 NZ NZ511062A patent/NZ511062A/xx not_active IP Right Cessation
- 1999-09-13 DE DE69940206T patent/DE69940206D1/de not_active Expired - Lifetime
- 1999-09-13 EE EEP200100146A patent/EE05558B1/xx not_active IP Right Cessation
- 1999-09-13 SK SK605-2001A patent/SK287601B6/sk not_active IP Right Cessation
- 1999-09-13 JP JP2000569831A patent/JP2002524529A/ja active Pending
- 1999-09-13 AU AU62486/99A patent/AU757873B2/en not_active Ceased
- 1999-09-13 PT PT99949656T patent/PT1113810E/pt unknown
- 1999-09-13 CZ CZ20010916A patent/CZ302997B6/cs not_active IP Right Cessation
- 1999-09-13 EA EA200100362A patent/EA004270B1/ru not_active IP Right Cessation
- 1999-09-13 TR TR2001/00734T patent/TR200100734T2/xx unknown
- 1999-09-13 CN CNB998109045A patent/CN1236815C/zh not_active Expired - Fee Related
- 1999-09-13 BR BR9913705-4A patent/BR9913705A/pt not_active Application Discontinuation
- 1999-09-13 EP EP99949656A patent/EP1113810B1/en not_active Expired - Lifetime
- 1999-09-13 CA CA2343579A patent/CA2343579C/en not_active Expired - Fee Related
- 1999-09-13 AT AT99949656T patent/ATE418999T1/de active
- 1999-09-13 IL IL14187799A patent/IL141877A0/xx not_active IP Right Cessation
- 1999-09-13 HU HU0103630A patent/HU229038B1/hu not_active IP Right Cessation
- 1999-09-13 SI SI9931028T patent/SI1113810T1/sl unknown
- 1999-09-13 DK DK99949656T patent/DK1113810T3/da active
-
2001
- 2001-02-23 IS IS5856A patent/IS2631B/is unknown
- 2001-03-12 NO NO20011244A patent/NO327855B1/no not_active IP Right Cessation
- 2001-03-12 ZA ZA200102032A patent/ZA200102032B/en unknown
- 2001-03-13 US US09/805,840 patent/US7211252B2/en not_active Expired - Lifetime
- 2001-03-14 NO NO20011283A patent/NO20011283D0/no unknown
-
2009
- 2009-03-19 IL IL197686A patent/IL197686A0/en unknown
- 2009-03-23 CY CY20091100320T patent/CY1109413T1/el unknown
-
2010
- 2010-06-09 JP JP2010132110A patent/JP5378303B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-25 JP JP2013154324A patent/JP2013241441A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002524529A5 (enExample) | ||
| CA2343579A1 (en) | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists | |
| JP2003531129A5 (enExample) | ||
| JP2025016606A5 (enExample) | ||
| JP2023055871A5 (enExample) | ||
| MXPA02010059A (es) | Metodo para administrar un anticuerpo. | |
| AU2013322806C1 (en) | Combinations and uses thereof | |
| KR20230038738A (ko) | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 | |
| JP2005533001A5 (enExample) | ||
| JP2018516969A5 (enExample) | ||
| JP2017511376A5 (enExample) | ||
| JP2006506333A5 (enExample) | ||
| JP2015534578A5 (enExample) | ||
| JP2009518441A5 (enExample) | ||
| CA2624935A1 (en) | Anti-myostatin antibodies | |
| JP2014515763A5 (enExample) | ||
| JP2003503361A5 (enExample) | ||
| JP2009539841A5 (enExample) | ||
| JP2004510752A5 (enExample) | ||
| TW201024310A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine | |
| HRP20170342T1 (hr) | Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice | |
| WO2002053177A3 (en) | Agents and methods for treating pain | |
| TW201024315A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide | |
| JP2008510714A5 (enExample) | ||
| JP2020510039A5 (enExample) |